PT-141
Also known as Bremelanotide, Vyleesi
An FDA-approved melanocortin receptor agonist for hypoactive sexual desire disorder (HSDD) in premenopausal women. PT-141 works through the central nervous system rather than the vascular system, making it effective for both men and women.
| Typical dose | 1-2 mg |
|---|---|
| Frequency | As needed, maximum once in 24 hours |
| Half-life | ~2.7 hours |
| Cycle length | As needed (not cycled) |
| Research level | extensive |
| Prescription required | Yes |
Mechanism of action
Activates melanocortin-4 receptors (MC4R) in the hypothalamus, stimulating dopaminergic pathways involved in sexual arousal. Unlike PDE5 inhibitors, it acts centrally rather than on blood vessels.
What this means in practice
PT-141 is one of the few compounds here with an FDA-approved counterpart: bremelanotide is sold as Vyleesi for hypoactive sexual desire disorder in premenopausal women, which means there is real regulatory review behind it. It acts centrally through melanocortin receptors rather than on blood flow, which is what distinguishes it mechanistically from PDE5 inhibitors. Onset is slow — hours, not minutes — so it's used with that lead time in mind. Nausea and flushing are the effects most often reported, and they track with dose.
Reported side effects
- Nausea
- Flushing
- Headache
- Increased blood pressure (transient)
Commonly stacked with
Track PT-141 properly
Log doses in one tap, watch the concentration curve update with real half-life math, and score outcomes to see whether it's working. Free, no account.
Get Optim on Google Play →This page is informational and summarises publicly available research. It is not medical advice, not a prescription, and not a recommendation to use any compound. Most compounds described here are not approved by the FDA for human use. Legal status varies by jurisdiction and is yours to determine. Talk to a qualified clinician before starting, stopping, or changing any protocol. For adults 18+. Optim does not sell, source, or recommend suppliers.